tiprankstipranks
Trending News
More News >
Biophytis Sa (BPTSY)
:BPTSY
Advertisement

Biophytis (BPTSY) Price & Analysis

Compare
37 Followers

BPTSY Stock Chart & Stats

$1.60
-$1.35(-31.02%)
At close: 4:00 PM EST
$1.60
-$1.35(-31.02%)

Biophytis News

BPTSY FAQ

What was Biophytis Sa’s price range in the past 12 months?
Biophytis Sa lowest stock price was $1.18 and its highest was $4.42 in the past 12 months.
    What is Biophytis Sa’s market cap?
    Biophytis Sa’s market cap is $4.43M.
      When is Biophytis Sa’s upcoming earnings report date?
      Biophytis Sa’s upcoming earnings report date is Feb 23, 2026 which is in 106 days.
        How were Biophytis Sa’s earnings last quarter?
        Biophytis Sa released its earnings results on Nov 04, 2025. The company reported -$1.962 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.962.
          Is Biophytis Sa overvalued?
          According to Wall Street analysts Biophytis Sa’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Biophytis Sa pay dividends?
            Biophytis Sa does not currently pay dividends.
            What is Biophytis Sa’s EPS estimate?
            Biophytis Sa’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Biophytis Sa have?
            Biophytis Sa has 3,501,216 shares outstanding.
              What happened to Biophytis Sa’s price movement after its last earnings report?
              Biophytis Sa reported an EPS of -$1.962 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.55%.
                Which hedge fund is a major shareholder of Biophytis Sa?
                Currently, no hedge funds are holding shares in BPTSY

                Company Description

                Biophytis Sa

                Biophytis (BPTSY) is a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases. The company's product pipeline includes drug candidates targeting neuromuscular diseases such as sarcopenia and other conditions like severe respiratory failure in COVID-19 patients. Biophytis utilizes its proprietary technology platforms to advance its research and development efforts in these areas.

                Biophytis (BPTSY) Earnings & Revenues

                Similar Stocks
                Company
                Price & Change
                Follow
                Oragenics
                InMed Pharmaceuticals
                Pasithea Therapeutics Corp
                SciSparc Ltd.
                Onconetix
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis